75
Views
12
CrossRef citations to date
0
Altmetric
Review

Phosphodiesterase-5 inhibitors in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia

, , , &
Pages 1687-1693 | Published online: 21 Jun 2008
 

Abstract

Background: Lower urinary tract symptoms (LUTS) are prevalent in ageing men and commonly coexist with erectile dysfunction. Preclinical data on the involvement of the nitric oxide/cyclic guanosine monophosphate/phosphodiesterase pathway in the regulation of lower urinary tract smooth muscle activity have been available for several years. Phosphodiesterase 5 (PDE5) is expressed in the prostate and bladder and PDE5 inhibitors have been shown to relax precontracted muscle strips from these organs. Objective: To assess the clinical benefit of PDE5 inhibitors in LUTS treatment. Methods: Clinical trials published as full papers in peer-reviewed journals were reviewed. Results/conclusion: Data from early clinical trials show a consistent improvement in International Prostate Symptom Score with PDE5 inhibitor therapy in men presenting with erectile dysfunction or LUTS. The lack of significant changes in objective outcomes in these trials, despite symptomatic improvement, reflects gaps in our understanding of LUTS pathophysiology/PDE5 inhibitors' mechanism of action. More trials are needed to further establish the clinical benefit of PDE5 inhibitors in LUTS treatment and to set criteria for patient and drug selection.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.